<DOC>
	<DOCNO>NCT00846430</DOCNO>
	<brief_summary>Patients neurofibromatosis type 1 ( NF1 ) commonly develop non-cancerous tumor call plexiform neurofibroma . These tumor define `` high-risk '' result severe pain , physical disability , organ dysfunction and/or become life-threatening . Presently , effective medical therapy offer patient `` high-risk '' plexiform neurofibroma , surgery provide last help . This study evaluate effectiveness two treatment combination patient `` high-risk '' plexiform neurofibroma .</brief_summary>
	<brief_title>Medical Treatment `` High-Risk '' Neurofibromas</brief_title>
	<detailed_description>The study 's design involve treat eligible patient combination celecoxib pegylated interferon alpha-2b . If patient least partial response six month , may continue treatment two year . If patient experience less partial response , progressive disease six month therapy , vincristine temozolomide add celecoxib interferon alpha-2b backbone . Response treatment assess minimum six month , presume patient experience progressive disease . Total duration therapy study two year individual treatment plan .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>`` HighRisk '' Plexiform Neurofibromas associate diagnosis NF1 230 year old ( minimum bodyweight 10 kilogram ) Adequate renal function Previously untreated active optic glioma History previous allergy study medication History ischemic vascular disease Pregnancy / Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Neurofibromas</keyword>
	<keyword>Neurofibromatosis 1</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Celebrex</keyword>
	<keyword>Peg-Interferon alpha-2b</keyword>
	<keyword>PEG-Intron</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Vincristine Sulfate</keyword>
	<keyword>Oncovin</keyword>
</DOC>